Clinical Trials Directory
Clinical Trials match your criteria
-
Retrospective Analysis of Adaptive Planning in ViewRay Treatments for Evaluation of Adaptive Plan Efficiency and its Impact on Dosimetry
Retrospective Analysis of Adaptive Planning in ViewRay Treatments for Evaluation of Adaptive Plan Efficiency and its Impact on Dosimetry
-
Phase 2, Magrolimab plus FOLFIRI/BEV in mCRC
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)
-
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
-
COLORECTAL CANCER CLINICAL VALIDATION STUDY TO PREDICT RECURRENCE USING A CIRCULATING TUMOR DNA ASSAY TO DETECT MINIMAL RESIDUAL DISEASE
CORRECT-MRD II: Second COloRectal cancer clinical validation study to predict Recurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease
-
ADP-A2M4CD8 as Monotherapy or in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy Of ADP-A2M4CD8 as Monotherapy or in Combination with Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors (SURPASS)
-
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CHS-006, as Monotherapy and in Combination with Toripalimab, in Participants with Advanced Solid Tumors
-
NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)
NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)
-
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
-
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART)
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More